The person who walks into a screening visit today has usually done their homework. They have searched online, read articles, and perhaps connected with patient groups before anyone from the study team said a word. They are not a blank slate, and treating them like one is the fastest way to lose them. Trust and transparency are no longer optional. They are the starting point.
Establishing authentic relationships with trial participants starts with a mindset shift: participants are not data points or case files. They’re people with lives, responsibilities, and a growing knowledge of their rights. They’re asking smarter questions and expect straightforward answers.
The “doctor knows best” mindset no longer applies to most patients. While a doctor’s expertise remains vital, the dynamic has changed. It’s now about a partnership. Be prepared to discuss what they’ve learned and address any questions or misconceptions they might bring. This shows respect for their initiative. The new reality is not a challenge; it’s an opportunity to build stronger, more meaningful partnerships.
Earning Clinical Trial Trust Means Meeting Patients Where They Are
Clinical trial trust isn’t built with one well-crafted information sheet. It’s an ongoing process that starts before the first handshake and continues well after the final data point is collected. Consider what trust looks like from the patient’s point of view: When a patient begins their journey into a clinical trial, they’ve likely already spent hours reading articles, scanning forums, or talking to others with similar conditions. They want to know: Is this study legitimate? Will it actually help? Who’s funding it? What happens if something goes wrong?
Trust is built by being honest about the goals of the research, potential risks, expected outcomes, and what participation involves, without burying this information in jargon or legalese. Don’t shy away from discussing the potential downsides, uncertainties, and time commitments of a trial. Savvy participants appreciate honesty. Trying to gloss over challenges will likely backfire and erode clinical trial trust quickly.
Be open about funding and any conflicts. In this age of information, details about trial funding are often accessible. Be upfront about sponsorship and address any potential perceived conflicts of interest directly. Transparency here is key. When you share information, also point them towards reputable, independent sources where they can learn more if they wish. This reinforces your message and shows you’re confident in the facts.
Transparency Is More Than Fine Print
Today’s informed patients don’t just want a seat at the table. They want a voice. That means sharing why the study was designed a certain way, how their feedback will be used, and how the results may benefit future patients. Be ready to answer the tough questions and admit when you don’t have all the answers. If someone asks a question you can’t immediately answer, it’s perfectly okay to say so and commit to finding out. This honesty builds more trust than guessing or giving a vague reply.
Plain language is non-negotiable. If you want trust, ditch the overly technical jargon when speaking with patients. Explain complex concepts clearly and simply. If they don’t understand what you’re saying, how can they truly trust the process? Open Q&A sessions and ongoing communication also help patients feel seen and respected. Offer alternatives. If an in-person visit is difficult, can telehealth be an option? If a side effect arises, how quickly can they expect support?
When people see real effort being made to simplify, clarify, and adapt communications to their needs, their sense of value increases. It’s not just about what’s said, but how and when. Keeping them informed throughout the trial, not just at the start, can be the difference between a positive and a frustrating experience.
Working With Informed Patients, Not Around Them
The old model of recruitment assumed patients knew little and needed hand-holding. That assumption no longer holds and does more harm than good. Informed patients are often highly motivated and educated about their condition. They ask thoughtful questions about mechanisms of action, dosing schedules, and potential off-label implications. Some trial teams find this intimidating, but it doesn’t need to be. In fact, it can be a gift.
These participants bring unique insights into trial design, and their early feedback can help identify potential drop-off points or practical concerns that may not be obvious to researchers. Collaboration isn’t just possible. It’s essential. Informed patients can flag overly complex documentation, identify pain points in logistics, and suggest improvements that make the entire process smoother. Tools like eConsent platforms, digital diaries, and real-time dashboards also help participants stay involved on their own terms.
Listen more than you speak. Before launching into explanations, ask people what they already know or what their main concerns are. This allows you to tailor your conversation and shows you value their existing knowledge. It’s a two-way street: the more participants feel heard, the more likely they are to provide useful feedback and stay the course, and the quality of the data follows.
Building trust isn’t just about the initial consent discussion. Maintain open lines of communication throughout the trial. Regular updates and being available for questions helps maintain that trust.
Bridging the Trust Gap with Diversity and Inclusion
Not all patients have the same history with medical research. Some communities carry justified skepticism due to past abuses. To build trust here, transparency must be coupled with cultural humility and intentional outreach. Work with community advocates and involve patients in protocol planning to address these hurdles up front. Representation matters, and when participants see themselves reflected in the study design and communication, it reinforces that their voice matters, too.
Diverse trial teams, inclusive recruitment materials, and partnerships with community leaders all help signal that the trial is safe and relevant. Listening sessions with underrepresented populations can surface barriers that generic recruitment misses. Transportation challenges, language access, or care responsibilities often deter participation. Lack of interest rarely does.
Long-standing trust is earned through consistency across all channels. Ensure the information people receive from different team members, or see on your website, is consistent. Mixed messages are a sure way to create confusion and suspicion. When people from diverse backgrounds see ongoing efforts, not just one-off campaigns, they begin to believe that their inclusion is real and lasting.
Building Long-Term Trust Beyond One Trial
Trust doesn’t stop when the trial ends. Participants deserve to know the impact of their involvement. Sharing results, even in lay terms, affirms their contribution and shows follow-through. It also opens the door for future participation and word-of-mouth recommendations. Maintaining relationships with former participants creates a pool of experienced individuals who may take part in future trials, act as peer advisors, or share their stories with people considering a study. This type of advocacy is built on respect, not incentives.
A truly informed patient makes their own choice. If, after all the transparent discussions, they decide a trial isn’t right for them, respect that decision. This professionalism reinforces a trustworthy reputation for future interactions.
When people feel genuinely appreciated and informed throughout the process, they become champions for research, not just subjects of it. That is the shift from transactional to relational engagement, and it begins before consent, with information a person can actually understand. See what trialport does for sponsors and CROs
About the author
Keith Berelowitz has spent more than twenty years watching clinical trials work on paper and struggle in real life. He has helped run studies, advises sponsors and CROs on how they engage with people, and chairs a UK research ethics committee, where consent forms and participant information sheets cross his desk every month. That vantage point led to one conclusion: most trial problems are not failures of science. They are failures of understanding at the moment a person decides.
He founded trialport, a clinical trial navigation and decision-support platform, on a principle he brings from the ethics committee: clarity is an ethical issue, not only a communication one. People should understand what they are being asked to consider before they are asked to decide. Understanding comes first. Decisions follow.